Can a Negative Urine THC Screen Conceal Surfactant Interference? What a 45-Specimen Study Found

Short answer: Yes. In a controlled 2026 forensic-analytical investigation, some urine specimens containing the cannabis metabolite THC-COOH gave negative lateral-flow immunoassay results after laboratory-induced interference with cationic surfactants. A second, controlled analytical challenge distinguished the 15 masked specimens from 15 genuinely negative specimens in a deliberately constructed, blinded 45-specimen panel. The evidence demonstrates a vulnerability of the evaluated screening methods—not a general false-negative rate in patients, proof of cannabis impairment, or a validated diagnosis that a particular donor intentionally adulterated a specimen.

The primary research is Finn, Huffman, and Skogerboe (2026), ACS Omega, “Behind the Mask: Detection and Characterization of Benzalkonium Chloride Adulteration in Immunoassay-Based Urine Drug Testing for Tetrahydrocannabinol (THC)”. Its findings concern the behavior of specific urinary THC-COOH screening antibodies in the presence of a possible matrix interferent. They do not concern a direct assay of psychoactive THC in venous whole blood.

What does a negative urine THC immunoassay ordinarily mean?

A screening result means that the specimen did not produce an immunochemical response meeting the particular test’s reporting rule under the conditions in which it was tested. It is not a universal chemical declaration that no cannabinoid is present. The commercial lateral-flow formats examined in the study used a nominal 50 ng/mL cutoff for the urinary metabolite 11-nor-9-carboxy-Δ9-tetrahydrocannabinol (THC-COOH). That threshold is a screening decision point, not a direct determination of brain exposure, psychomotor function, when cannabis was used, or whether a vehicle operator was impaired.

Urine is principally an excretion specimen. THC-COOH is a metabolite of THC, not the same substance as parent Δ9-THC circulating in blood. A negative urinary screen therefore cannot be translated automatically into either a negative whole-blood result or an absence of drug-related effects at some different time. Equally, a positive screen cannot establish a legally relevant level of impairment without separate case evidence and analytical interpretation.

What interference did the investigators actually study?

The researchers evaluated benzalkonium chloride (BAK), a family of positively charged, surface-active quaternary ammonium compounds used in some consumer formulations. They asked whether surfactant-related changes in the sample matrix could prevent the test from registering THC-COOH even when the metabolite was present. Several products with different ingredient formulations and independently prepared laboratory materials were examined. The resulting data showed matrix-dependent masking of the test response; product identity and ingredient labeling alone did not give a reliable quantitative prediction.

The proposed explanation involves surfactant self-association and possible partitioning of THC-COOH into aggregates that make the analyte less available to interact with the antibody system. That is a chemically plausible mechanism discussed by the authors. The experiments did not directly image individual micelles holding individual THC-COOH molecules or uniquely prove that this mechanism explains every negative result. Some effects may also depend on the specimen’s ionic composition, the formulation, or the particular test design.

The article’s central forensic lesson is consequently narrower than “surfactants always hide THC”: an interferent can alter the response of the screening system, and that possibility must be addressed with appropriate analytical controls rather than inferred from a single negative strip.

How was the investigation designed—and who were the 45 specimens?

The study combined laboratory characterization of surfactant-associated effects with a subsequent blinded evaluation of a proposed interference-detection approach. The validation panel comprised 45 constructed urine test specimens allocated equally to three known categories: 15 expected screening positives, 15 authentic screening negatives, and 15 specimens engineered to contain detectable THC-COOH while yielding a misleading negative screening response. The number 45 should not be presented as 45 independently recruited patients or drivers, a population-based survey, or 45 confirmed examples of real-world tampering.

Student teams in an upper-division forensic-science setting interpreted coded specimens. The same panel categories were evaluated with two commercial lateral-flow product lines, identified in the article as iCass and EZH. The two devices were not two independent cohorts of 45 people; findings from the same prepared panel are correlated. The design tested whether the proposed method could distinguish deliberately produced interference from a genuine negative result under controlled conditions.

What happened on the first urine screen?

The ordinary first screening step identified all 15 expected positive specimens as positive and identified the 15 true negatives as negative. However, it also returned negative responses for the 15 deliberately masked specimens. With the study’s known classification treated as the reference, this produced the authors’ reported sensitivity of 50% when counting 15 detected positives out of 30 specimens that in fact contained THC-COOH, alongside 100% specificity among 15 known negatives.

These percentages are mathematically correct for this constructed, balanced laboratory panel. They do not mean that commercial urine THC screens have 50% sensitivity in typical clinical practice, that half of all positive patient samples are concealed, or that every benzalkonium-containing product produces the same outcome. The challenge was intentionally enriched with false negatives; it was not a representative series of routine urine submissions.

What did the additional analytical challenge show?

The investigators applied a second controlled check to samples that initially screened negative. In the 15 genuinely negative samples, that check produced the expected positive response to the laboratory’s added reference material. In the 15 masked specimens, the screening system still failed to respond as expected. This distinction allowed the investigators to flag all 15 masked specimens in the study’s blinded classification exercise. The same separation was reported for the two evaluated lateral-flow brands.

Importantly, this was an interference-recognition experiment, not mass-spectrometric proof that a particular donor used cannabis. Detecting a suppressed response when an assay is challenged indicates an abnormal analytical matrix or other interference requiring investigation. The challenge does not uniquely identify BAK, establish its source, or confirm the amount of THC-COOH originally present in a real unknown specimen. It should prompt documented confirmatory analysis, supervised recollection when justified, and investigation of specimen handling rather than an automatic accusation.

What does the evidence table actually show?

The authors summarized first-pass sensitivity as 50% and the combined procedure’s sensitivity and specificity as 100% under their reference classification. The more important explanation is the underlying numerator, denominator, and deliberate panel composition. Reporting only “100% reliable” without these qualifications would falsely imply broad real-world validation.

Why might ordinary specimen-validity testing fail to reveal this interference?

Standard specimen-validity checks commonly assess selected properties such as pH, creatinine, specific gravity, oxidants, or specific chemical adulterants. They cannot be assumed to detect every surfactant or every other substance capable of changing an antibody response. In the investigators’ controlled tests, ordinary validity-screening observations did not reliably reveal the conditions that caused the THC-COOH assay to fail.

A specimen may consequently look unremarkable under one validity panel while still behaving abnormally in an analyte-specific assay. That is not proof that the validity panel was operated incorrectly. It illustrates the difference between checking a limited set of specimen properties and testing the analytical method’s susceptibility to matrix interference. A laboratory should identify the exact validity methods used and what each actually measures before interpreting either a normal or abnormal result.

Collection history, container integrity, accessioning, storage, temperature, and documented transfer between handlers remain independent matters. The laboratory’s specimen-integrity evidence must be evaluated alongside its testing controls, not replaced by a presumed mechanism.

Can a surfactant-detection dye specifically prove benzalkonium chloride was present?

No. The researchers also evaluated a dye-binding spectrophotometric approach involving Eosin Y to characterize cationic surface-active material in consumer products. Such a response can help screen for relevant chemical behavior, but it is not exclusively selective for benzalkonium chloride. In the original product comparison, a sample without reported BAK produced a dye response plausibly attributable to other cationic surfactants.

Formulation labels, nominal ingredient amounts, spectrophotometric estimates, and the assay’s actual urine matrix therefore answer different questions. A dye-binding signal is not a compound-specific identification by a validated reference method. Nor does it establish a motive for adding anything to a submitted urine sample. Where identification of a foreign substance is material to a legal dispute, the claim should rest on an appropriately validated and documented method for that substance, not the appearance of a generic color change.

Does the study establish why the urine screen turned negative?

The findings are consistent with a surfactant-associated matrix effect, but they do not isolate every molecular mechanism. Changes in ionic environment, analyte distribution, reagent behavior, device design, and specimen-to-specimen variation may contribute. The researchers reported considerable heterogeneity across the tested materials and urine specimens, cautioning against a simple threshold or a deterministic prediction based solely on an ingredient list.

For expert interpretation, distinguish three questions: was the target metabolite present in the designed experiment; did a lateral-flow immunoassay respond; and was a specific chemical interferent independently identified? A yes to the first and a no to the second demonstrates analytical discordance under test conditions. It does not automatically answer the third question for an evidentiary specimen.

What is the difference between interference screening and confirmation?

For compound-specific drug identification, a laboratory may use an appropriately validated chromatographic mass-spectrometric method whose extraction, internal standard, quality controls, and acceptance criteria address the relevant matrix. The original authors discussed methods resistant to the examined interference, but did not thereby validate every possible LC–MS/MS or GC–MS workflow for every contaminant or specimen. The distinction is expanded in this site’s confirmatory drug testing guide.

Does a negative urine screen prove that a witness, defendant, or patient abstained from cannabis?

Not categorically. An individual’s result also depends on time since exposure, urine dilution, metabolite excretion, the cutoff, antibody cross-reactivity, collection conditions, and the possibility of interference. A negative result can be accurate under the test’s specified reporting rule and yet not establish absence of all prior exposure. Conversely, the mere existence of interference research does not justify rejecting every negative THC screen or presuming adulteration in a disputed case.

Where legal consequences turn on this result, the appropriate questions include which substance and specimen were tested, whether the original result was screening or confirmation, what validity panel was performed, whether the specimen was retained, what chromatographic confirmation is available, what analytical uncertainty exists, and whether controls disclosed any interference. A separate explanation of biological matrices in toxicology shows why urine should not be casually substituted for a contemporaneous blood assay.

What should an attorney or forensic expert scrutinize in the actual laboratory record?

Begin with the exact proposition being offered. If the claim is that a particular sample screened negative, obtain the device manufacturer, lot, nominal threshold, quality-control logs, validation scope, original photographs or electronic readout, result transcription, collection and storage information, and complete chain-of-custody. If the claim advances to intentional adulteration, seek independently confirmed identification of the suspect interferent, evidence of specimen access, and a documented alternative-explanation assessment.

Review whether any sample-response control was performed, how it was interpreted, and whether it was validated for evidentiary use rather than merely demonstrated in a teaching laboratory. Examine whether a confirmatory assay tested the same retained original specimen and distinguished THC-COOH from parent THC or other metabolites. Preserve the difference between a missing analyte response, a chemical identification, and an accusation about human conduct. Collection and preservation questions are discussed in the site’s specimen collection guide.

Finally, look for adverse facts: differing device behavior, known matrix effects, failed or omitted controls, lack of an independently confirmed adulterant, and absence of appropriate comparison specimens. The 45-specimen laboratory panel is useful impeachment or method-reliability context only to the extent its setup resembles the contested analytical method. It is not itself a validation study of a particular defendant’s sample or proof of an intent to deceive.

What can—and cannot—the findings establish in litigation?

What they establish: controlled laboratory material can cause false-negative responses in evaluated urine THC-COOH lateral-flow immunoassays; a secondary assay-response challenge distinguished those abnormal responses from true negatives in the constructed blinded panel. The study also shows why general specimen-validity checks and nonspecific surfactant responses are not interchangeable with analyte-specific validation.

What they do not establish: the prevalence of BAK adulteration in actual urine submissions; verified intentional adulteration by any named person; accuracy of every product or external laboratory; a person’s parent-THC whole-blood concentration; cannabis-induced impairment; or causal responsibility for an accident. These require different evidence. A scientifically qualified opinion must remain bounded by the measured specimen, validated method, time, and question.

Frequently asked questions

Could a genuinely THC-COOH-containing urine specimen screen negative?

Yes. The authors experimentally produced masked, metabolite-containing urine specimens that screened negative on the evaluated lateral-flow tests. This establishes a possible analytical failure mode, not its frequency in routine specimens.

Were 45 separate cannabis users recruited?

No. The blinded evaluation involved 45 deliberately constructed test specimens in three known groups of 15, not a representative cohort of 45 drug users.

Did both evaluated test brands miss the deliberately masked specimens?

Yes. The reported blinded exercise found the same category-level first-screen misclassification pattern for iCass and EZH. The two brands’ evaluations do not represent independent patient cohorts.

Does the additional analytical challenge chemically prove benzalkonium chloride?

No. It flags an unexpectedly suppressed screening response consistent with interference and warrants additional investigation. The particular interferent’s identity and origin require independent evidence.

Can ordinary validity strips exclude every surfactant?

No. Each validity assay checks specified properties or chemicals. A normal result does not establish that every possible matrix interferent has been excluded.

Would a validated confirmation resolve whether THC-COOH is present?

An appropriately validated compound-specific confirmatory analysis can address the identity and amount of THC-COOH in the tested specimen within its own performance limits. Confirmation alone does not establish impairment or intentional tampering.

Can this paper determine whether someone was impaired while driving?

No. It examined laboratory urine-screening interference, not blood THC pharmacokinetics, observed driving, crash responsibility, or individual behavioral impairment.

Primary source: Finn E, Huffman J, Skogerboe KJ. ACS Omega (2026). DOI: 10.1021/acsomega.6c03171. The original article should be consulted for the complete methods, controls, source tables, and experimental conditions; no individual case conclusion is implied by the present analysis.